Arlington Partners LLC Buys 1,981 Shares of Danaher Co. (NYSE:DHR)

Arlington Partners LLC grew its position in shares of Danaher Co. (NYSE:DHR) by 16.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 14,351 shares of the conglomerate’s stock after purchasing an additional 1,981 shares during the period. Arlington Partners LLC’s holdings in Danaher were worth $3,990,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of the company. Tsfg LLC grew its position in Danaher by 733.3% during the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after acquiring an additional 88 shares during the last quarter. CarsonAllaria Wealth Management Ltd. purchased a new position in Danaher in the 2nd quarter worth $25,000. nVerses Capital LLC bought a new stake in Danaher in the second quarter worth $25,000. Redmont Wealth Advisors LLC bought a new position in shares of Danaher during the first quarter valued at about $30,000. Finally, MFA Wealth Advisors LLC bought a new stake in shares of Danaher in the 2nd quarter valued at about $51,000. 79.05% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

DHR has been the subject of several recent research reports. Stifel Nicolaus boosted their price objective on Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a research report on Wednesday, July 24th. Robert W. Baird upped their price target on shares of Danaher from $271.00 to $278.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. Royal Bank of Canada reissued an “outperform” rating and issued a $300.00 price target on shares of Danaher in a report on Friday, September 6th. StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a report on Tuesday, June 25th. Finally, Leerink Partners boosted their price target on Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. Seven research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $282.12.

Danaher Stock Down 1.3 %

Shares of DHR traded down $3.62 during mid-day trading on Monday, reaching $270.76. The company had a trading volume of 557,585 shares, compared to its average volume of 2,707,091. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $281.70. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. The company has a market capitalization of $200.55 billion, a price-to-earnings ratio of 46.51, a price-to-earnings-growth ratio of 4.49 and a beta of 0.83. The firm has a 50-day moving average price of $270.72 and a 200 day moving average price of $260.13.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. The firm had revenue of $5.74 billion for the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The company’s quarterly revenue was down 2.9% on a year-over-year basis. During the same period in the prior year, the firm posted $2.05 earnings per share. On average, sell-side analysts forecast that Danaher Co. will post 7.59 EPS for the current year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be paid a dividend of $0.27 per share. The ex-dividend date of this dividend is Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.40%. Danaher’s dividend payout ratio is currently 18.31%.

Insider Transactions at Danaher

In related news, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at $1,130,374.44. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now directly owns 4,212 shares in the company, valued at approximately $1,130,374.44. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Brian W. Ellis sold 9,600 shares of the company’s stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the transaction, the senior vice president now owns 20,230 shares in the company, valued at $5,566,486.80. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 39,659 shares of company stock worth $11,042,433. Corporate insiders own 11.10% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.